Articles related to IMMUNOTHERAPY

The encouraging results of the phase 3 ORIENT-11 trial, which included 397 patients with previously untreated, locally advanced metastatic non-squamous NSCLC without sensitizing EGFR or ALK aberrations, were published in the Journal of Thoracic Oncology.

The case reported is based on a 53-year-old woman who presented to her gastroenterologist with symptoms of bowel obstruction and right upper quadrant pain. Based on her age and excellent performance status, aggressive treatment with a triplet chemotherapy regimen of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (FOLFOXIRI) in combination with the anti–vascular endothelial growth factor receptor antibody bevacizumab was begun.

A late-breaking abstract from the ASH Annual Meeting & Exhibition. In this double-blind, placebo-controlled, international study of 879 patients (median age: 65 (range 19–80) years; IPI 3–5 (62%)), the pola-R-CHP combination demonstrated a 27% reduction in the relative risk of disease progression, relapse, or death compared with R-CHOP, with a similar safety profile in the first-line treatment of patients with DLBCL.

A randomized phase II trial has found that consolidation therapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) after chemoradiotherapy did not lead to better survival outcomes for patients with small cell lung cancer (SCLC). The study enrolled 222 patients with stage I-IIIB histologically or cytologically confirmed limited-disease SCLC, and adequate hematologic, renal, lung, and pulmonary function. The combination regimen yielded no improvement in overall survival, and grade 3 adverse events were approximately 2.5 times more common in the dual therapy group.

Publication: JAMA OncologyMethod: Retrospective study of 160 adults with hematologic malignant disease who were vaccinated with 1 of 3 COVID-19 vaccines (February through April 2021).Results: Patients receiving B-cell-depleting immunotherapy may not gain adequate protection from vaccination and may still develop a potentially fatal infection.

An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer.